Autoantibodies directed against the protease inhibitor calpastatin in psoriasis

Clinical and Experimental Immunology

Volumn 139, Issue 2, 2005, Pages 355-362

  Matsushita, Y ^a   Shimada, Y ^a   Kawara, S ^a   Takehara, K ^a   Sato, Shinichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Autoantibody; Calpain; Calpastatin; Psoriasis

Indexed keywords

ANTIBODY; AUTOANTIBODY; CALPAIN; CALPAIN II; CALPASTATIN; CALPASTATIN ANTIBODY; IMMUNOGLOBULIN G; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; CALCIUM-BINDING PROTEINS; CALPAIN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; SKIN;

EID: 13544250481     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02701.x     Document Type: Article

References (37)

1. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135:1104-10.
2. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20:40-6.
3. Ghoreschi K, Thomas P, Breit S et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9:40-6.
4. Barker JN. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998; 59:530-3.
5. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301:555.
6. + T cells induces psoriasis. Am J Pathol 1999; 155: 145-58.
7. Jablonska S, Chorzelski TP, Beutner EH, Maciejowska E, Jarzabek C, Rzesa G. Autoimmunity in psoriasis. Relation of disease activity and forms of psoriasis to immunofluorescence findings. Arch Dermatol Res 1978; 261:135-46.
8. Qutaishat SS, Kumar V, Beutner EH, Jablonska S. A distinct stratum corneum antigen in psoriasis and its reactions with stratum corneum autoantibodies. APMIS 1992; 100:341-6.
9. Tagami H, Iwatsuki K, Yamada M. Profile of anti-stratum corneum autoantibodies in psoriatic patients. Arch Dermatol Res 1983; 275:71-5.
10. Aoki S, Yaoita H, Kitajima Y. An elevated level of autoantibodies against 48- to 50-kd keratins in the serum of patients with psoriasis. J Invest Dermatol 1989; 92:179-83.
11. Rivers JK, Podgorski MR, Colliding NJ et al. The presence of autoantibody to recombinant lipocortin-I in patients with psoriasis and psoriatic arthritis. Br J Dermatol 1990; 123:569-72.
12. Croall DE, DeMartino GN. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev 1991; 71:813-47.
13. Saido TC, Sorimachi H, Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 1994; 8:814-22.
14. Wang KK, Yuen PW. Calpain inhibition: an overview of its therapeutic potential. Trends Pharmacol Sci 1994; 15:412-19.
15. Cuzzocrea S, McDonald MC, Mazzon E et al. Calpain inhibitor I reduces the development of acute and chronic inflammation. Am J Pathol 2000; 157:2065-79.
16. Emori Y, Kawasaki H, Imajoh S, Minami Y, Suzuki K. All four repeating domains of the endogenous inhibitor for calcium-dependent protease independently retain inhibitory activity. Expression of the cDNA fragments in Escherichia coli. J Biol Chem 1988; 263:2364-70.
17. Garach-Jehoshua O, Ravid A, Liberman UA, Reichrath J, Glaser T, Koren R. Upregulation of the calcium-dependent protease, calpain, during keratinocyte differentiation. Br J Dermatol 1998; 139:950-7.
18. Mimori T, Suganuma K, Tanami Y et al. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci USA 1995; 92:7267-71.
19. Despres N, Talbot G, Plouffe B, Boire G, Menard HA. Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest 1995; 95:1891-6.
20. Saulot V, Vittecoq O, Salle V et al. Autoantibodies directed against the amino-terminal domain I of human calpastatin (ACAST-DI Ab) in connective tissue diseases. High levels of ACAST-DI Ab are associated with vasculitis in lupus. J Autoimmun 2002; 19:55-61.
21. Vittecoq O, Salle V, Jouen-Beades F et al. Autoantibodies to the 27 C-terminal amino acids of calpastatin are detected in a restricted set of connective tissue diseases and may be useful for diagnosis of rheumatoid arthritis in community cases of very early arthritis. Rheumatology 2001; 40:1126-34.
22. Suzuki K, Shimizu K, Hamamoto T, Nakagawa Y, Murachi T, Yamamuro T. Characterization of proteoglycan degradation by calpain. Biochem J 1992; 285:857-62.
23. Sato S, Hasegawa M, Nagaoka T et al. Autoantibodies against calpastatin in sera from patients with systemic sclerosis. J Rheumatol 1998; 25:2135-9.
24. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
25. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
26. Imajoh S, Kawasaki H, Suzuki K. Limited autolysis of calcium-activated neutral protease (CANP): reduction of the Ca2+-requirement is due to the NH2-terminal processing of the large subunit. J Biochem (Tokyo) 1986; 100:633-42.
27. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diag 2001; 3:55-61.
28. Kunimatsu MH, Igashiyama S, Sato K, Ohkubo I, Sasaki M. Calcium dependent cysteine proteinase is a precursor of a chemotactic factor for neutrophils. Biochem Biophys Res Commun 1989; 164:875-82.
29. Pontremoli S, Melloni E, Damiani G et al. Effects of a monoclonal anti-calpain antibody on responses of stimulated human neutrophils. Evidence for a role for proteolytically modified protein kinase C. J Biol Chem 1988; 263:1915-19.
30. Kobayashi Y, Yamamoto K, Saido T, Kawasaki H, Oppenheim JJ, Matsushima K. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1α. Proc Natl Acad Sci USA 1990; 87:5548-52.
31. Debets R, Hegmans JP, Troost RJ, Benner R, Prens EP. Enhanced production of biologically active interleukin-1α and interleukin-1β by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1β levels and facilitated interleukin-1 release. Eur J Immunol 1995; 25:1624-30.
32. Groves RW, Mizutani H, Kieffer JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1α in basal epidermis. Proc Natl Acad Sci USA 1995; 92:11874-8.
33. Grossman RM, Krueger J, Yourish D et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86:6367-71.
34. de Boer OJ, Wakelkamp IM, Pals ST, Claessen N, Bos JD, Das PK. Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch Dermatol Res 1994; 286:304-11.
35. Miyachi Y, Yoshimura N, Suzuki S et al. Biochemical demonstration and immunohistochemical localization of calpain in human skin. J Invest Dermatol 1986; 86:346-9.
36. Fukui I, Tanaka K, Murachi T. Extracellular appearance of calpain and calpastatin in the synovial fluid of the knee joint. Biochem Biophys Res Commun 1989; 162:559-66.
37. Ortonne JP. Aetiology and pathogenesis of psoriasis. Br J Dermatol 1996; 135 (Suppl. 49):1-5.